HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

catumaxomab

Used in the treatment of malignant ascites in patients with metastatic cancers; binds EpCAM and CD3 antigens. Extracorporeal PBMNC coating with catumaxomab may be an option to control intravascular cytokine release induced by therapeutic antibodies
Also Known As:
removab
Networked: 86 relevant articles (16 outcomes, 34 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Lindhofer, Horst: 16 articles (10/2021 - 07/2007)
2. Ruf, Peter: 7 articles (10/2021 - 05/2010)
3. Bokemeyer, Carsten: 7 articles (10/2015 - 08/2010)
4. Jäger, Michael: 7 articles (06/2012 - 07/2007)
5. Wimberger, Pauline: 6 articles (12/2015 - 07/2007)
6. Sehouli, Jalid: 6 articles (09/2015 - 08/2009)
7. Seimetz, Diane: 6 articles (06/2014 - 03/2010)
8. Friccius-Quecke, Hilke: 5 articles (12/2014 - 10/2007)
9. Heiss, Markus M: 5 articles (06/2014 - 09/2010)
10. Lordick, Florian: 4 articles (01/2018 - 09/2008)

Related Diseases

1. Ascites
2. Neoplasms (Cancer)
3. Ovarian Neoplasms (Ovarian Cancer)
4. Stomach Neoplasms (Stomach Cancer)
5. Peritoneal Neoplasms

Related Drugs and Biologics

1. Epithelial Cell Adhesion Molecule
2. Cytokines
3. Monoclonal Antibodies
4. human ERBB2 protein
5. catumaxomab
6. Sirolimus (Rapamycin)
7. Platinum
8. Antibodies
9. Cetuximab (Erbitux)
10. Bevacizumab (Avastin)

Related Therapies and Procedures

1. Immunotherapy
2. Parenteral Infusions
3. Neoadjuvant Therapy
4. Drug Therapy (Chemotherapy)
5. Therapeutics